WO2011014872A3 - Compositions and methods for diagnosing, treating or preventing neoplasias - Google Patents

Compositions and methods for diagnosing, treating or preventing neoplasias Download PDF

Info

Publication number
WO2011014872A3
WO2011014872A3 PCT/US2010/044118 US2010044118W WO2011014872A3 WO 2011014872 A3 WO2011014872 A3 WO 2011014872A3 US 2010044118 W US2010044118 W US 2010044118W WO 2011014872 A3 WO2011014872 A3 WO 2011014872A3
Authority
WO
WIPO (PCT)
Prior art keywords
diagnosing
treating
methods
compositions
neoplasias
Prior art date
Application number
PCT/US2010/044118
Other languages
French (fr)
Other versions
WO2011014872A2 (en
Inventor
Anirban Maitra
Hector Alvarez
Original Assignee
The Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Johns Hopkins University filed Critical The Johns Hopkins University
Publication of WO2011014872A2 publication Critical patent/WO2011014872A2/en
Publication of WO2011014872A3 publication Critical patent/WO2011014872A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

As described below, the present invention features compositions and methods for diagnosing, treating and preventing neoplasias.
PCT/US2010/044118 2009-07-31 2010-08-02 Compositions and methods for diagnosing, treating or preventing neoplasias WO2011014872A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23015709P 2009-07-31 2009-07-31
US61/230,157 2009-07-31
US23480809P 2009-08-18 2009-08-18
US61/234,808 2009-08-18

Publications (2)

Publication Number Publication Date
WO2011014872A2 WO2011014872A2 (en) 2011-02-03
WO2011014872A3 true WO2011014872A3 (en) 2011-05-26

Family

ID=43529978

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/044118 WO2011014872A2 (en) 2009-07-31 2010-08-02 Compositions and methods for diagnosing, treating or preventing neoplasias

Country Status (1)

Country Link
WO (1) WO2011014872A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017345574A1 (en) 2016-10-19 2019-05-23 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods for treating cancer
WO2018183762A1 (en) 2017-03-29 2018-10-04 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020107284A1 (en) * 1998-06-29 2002-08-08 Parker Hughes Institute Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
US20050186571A1 (en) * 2002-07-17 2005-08-25 Max-Planck-Gesellschaft Zun Diagnosis and prevention of cancer cell invasion
US20090042906A1 (en) * 2007-04-26 2009-02-12 Massachusetts Institute Of Technology Methods for treating cancers associated with constitutive egfr signaling
US20090274693A1 (en) * 2008-05-05 2009-11-05 Gilmer Tona M Method of Treating Cancer using a cMet and AXL Inhibitor and an ErbB Inhibitor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020107284A1 (en) * 1998-06-29 2002-08-08 Parker Hughes Institute Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
US20050186571A1 (en) * 2002-07-17 2005-08-25 Max-Planck-Gesellschaft Zun Diagnosis and prevention of cancer cell invasion
US20090042906A1 (en) * 2007-04-26 2009-02-12 Massachusetts Institute Of Technology Methods for treating cancers associated with constitutive egfr signaling
US20090274693A1 (en) * 2008-05-05 2009-11-05 Gilmer Tona M Method of Treating Cancer using a cMet and AXL Inhibitor and an ErbB Inhibitor

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HOLLAND, S. J. ET AL.: "R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.", CANCER RES., vol. 70, no. 4, 9 February 2010 (2010-02-09), pages 1544 - 1554, XP002598062, DOI: doi:10.1158/0008-5472.CAN-09-2997 *
LAY, J. D. ET AL.: "Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL.", CANCER RES., vol. 67, no. 8, 15 April 2007 (2007-04-15), pages 3878 - 3887, XP002560531, DOI: doi:10.1158/0008-5472.CAN-06-3191 *
MALEY, C. C.: "Multistage carcinogenesis in Barrett's esophagus.", CANCER LETT., vol. 245, no. 1-2, 19 May 2006 (2006-05-19), pages 22 - 32, XP005813539, DOI: doi:10.1016/j.canlet.2006.03.018 *
ZHANG, Y. X. ET AL.: "AXL is a potential target for therapeutic intervention in breast cancer progression.", CANCER RES., vol. 68, no. 6, 15 March 2008 (2008-03-15), pages 1905 - 1915, XP002505662, DOI: doi:10.1158/0008-5472.CAN-07-2661 *

Also Published As

Publication number Publication date
WO2011014872A2 (en) 2011-02-03

Similar Documents

Publication Publication Date Title
WO2010062377A3 (en) Methods and compositions for the detection and treatment of preeclampsia
WO2011072099A3 (en) Compositions and methods comprising protease variants
WO2009108860A8 (en) Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
WO2011031896A3 (en) Pi3 kinase inhibitors and uses thereof
WO2011142858A3 (en) Chlorotoxin variants, conjugates, and methods for their use
WO2009130479A3 (en) Virus
WO2013119916A3 (en) Compounds for treating spinal muscular atrophy
UA104459C2 (en) Anti-fgfr3 antibodies and methods using same
WO2008094708A3 (en) Activin-actriia antagonists and uses for treating or preventing breast cancer
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2012061290A3 (en) Pesticidal compositions and processes related thereto
WO2010077740A3 (en) Novel antiviral compounds, compositions, and methods of use
WO2012009567A3 (en) Biomarkers for diagnosis of stroke and its causes
WO2011130222A3 (en) Compositions and methods comprising variant proteases
CA2830549C (en) Methods and compositions for preparing noribogaine from voacangine
EP2282735A4 (en) Compounds, compositions and methods for making the same
WO2011075636A3 (en) Wise binding agents and epitopes
WO2011133504A3 (en) Nanozymes, methods of making nanozymes, and methods of using nanozymes
WO2010118866A8 (en) Trehalulose-containing composition, its preparation and use
WO2011008773A3 (en) Mesenchymal stem cell differentiation
WO2009120810A3 (en) Neurodegenerative disorders
WO2008112659A3 (en) Regulation of osteopontin
WO2009092052A3 (en) Methods and compositions for treating polyps
WO2009129497A3 (en) Methods and compositions for treating age-related macular degeneration
WO2012018932A3 (en) Compounds and compositions for mitigating tissue damage and lethality

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10805170

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10805170

Country of ref document: EP

Kind code of ref document: A2